KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, today announced the appointment of J.D. Mowery as Chief Executive Officer (CEO).
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...
Through joint development with Bacchus Bio innovation, JSR will develop and produce raw materials for its key biomass products utilizing synthetic biology.
The new facility expands the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
Under the initial agreement, Similis will be responsible for cell line development, analytics, process development, and cGMP production, leading to pharmacokinetics/pharmacodynamic clinical trials
KBI Biopharma, Inc. announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclona...
Crown Bioscience announced today their newly published study in PLOS ONE demonstrating the establishment and application of a clinically relevant 3D in vitro PDX-derived organoid biobank for higher...
This product detects the SARS-CoV-2 and Influenza virus antigen in nasal swab fluid by the immunochromatography method. MBL can sell this product at pharmacies, drugstores and pharmacy online sites.
3 of 25
Receive JSR Life Sciences news on your RSS reader.